These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29877163)

  • 1. How Significant Are "High" Correlations Between EQ-5D Value Sets?
    Ombler F; Albert M; Hansen P
    Med Decis Making; 2018 Aug; 38(6):635-645. PubMed ID: 29877163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice.
    Yang Z; Luo N; Bonsel G; Busschbach J; Stolk E
    Value Health; 2019 Jan; 22(1):38-44. PubMed ID: 30661632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new tool for creating personal and social EQ-5D-5L value sets, including valuing 'dead'.
    Sullivan T; Hansen P; Ombler F; Derrett S; Devlin N
    Soc Sci Med; 2020 Feb; 246():112707. PubMed ID: 31945596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
    Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
    Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
    Pullenayegum EM; Chan KK; Xie F
    Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping Sri Lankan EQ-5D-3L to EQ-5D-5L Value Sets.
    Kularatna S; Chen G; Byrnes J; Scuffham PA
    Value Health Reg Issues; 2017 May; 12():20-23. PubMed ID: 28648311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Discrete Choice Experiments with Duration to Model EQ-5D-5L Health State Preferences.
    Mulhern B; Bansback N; Hole AR; Tsuchiya A
    Med Decis Making; 2017 Apr; 37(3):285-297. PubMed ID: 27681988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
    Craig BM; Rand K
    Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe.
    Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS
    Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L.
    Wong EL; Cheung AW; Wong AY; Xu RH; Ramos-Goñi JM; Rivero-Arias O
    Value Health; 2019 Aug; 22(8):916-924. PubMed ID: 31426933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward a Smaller Design for EQ-5D-5L Valuation Studies.
    Yang Z; Luo N; Oppe M; Bonsel G; Busschbach J; Stolk E
    Value Health; 2019 Nov; 22(11):1295-1302. PubMed ID: 31708067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting Health States for EQ-5D-3L Valuation Studies: Statistical Considerations Matter.
    Yang Z; Luo N; Bonsel G; Busschbach J; Stolk E
    Value Health; 2018 Apr; 21(4):456-461. PubMed ID: 29680103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.
    Hernandez Alava M; Wailoo A; Grimm S; Pudney S; Gomes M; Sadique Z; Meads D; O'Dwyer J; Barton G; Irvine L
    Value Health; 2018 Jan; 21(1):49-56. PubMed ID: 29304940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People's Quality of Life Brief Questionnaire (OPQoL-Brief) Scores.
    Kaambwa B; Ratcliffe J
    Patient; 2018 Feb; 11(1):39-54. PubMed ID: 28623629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brazilian Valuation of EQ-5D-3L Health States: Results from a Saturation Study.
    Santos M; Cintra MA; Monteiro AL; Santos B; Gusmão-Filho F; Andrade MV; Noronha K; Cruz LN; Camey S; Tura B; Kind P
    Med Decis Making; 2016 Feb; 36(2):253-63. PubMed ID: 26492896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.